TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
New findings from University of Groningen in the area of tuberculosis described
September 2nd, 2008
According to recent research from Netherlands, "Ethambutol (EMB) is one of the first-line drugs in the treatment against tuberculosis (TB). Side-effects are infrequent, but its main adverse effect, optical neuropathy, has long been recognised." "The mechanisms of action and predisposing factors have not yet been fully understood. We conducted a retrospective study (19922007) in an attempt to find predisposing factors for optical neuropathy. Visual disturbance was reported in 1.3% of the 760 patients treated with EMB; of these, 0.8% were EMB-related. We present the six cases; four were clearly overdosed, but in two obese patients dosage was correctly calculated for total...
Source: TB & Outbreaks Week (2008-09-02)
|
